Author: lappaadm

December 11, 2024 | Case Law Monitor

Case Law Monitor is the bimonthly case law newsletter of the Legislative Analysis and Public Policy Association (LAPPA). Each issue will highlight unique cases from around the United States in the areas of public health and safety, substance use disorders, and the criminal justice system. ...

December 3, 2024 | Controlled Substances, Model Laws, Peer Support and Recoery Services, Public Health, Recovery, Substance Misuse, Workforce Development

The purpose of the Model Building the Substance Use Disorder Workforce of the Future Act is to address the current and projected shortage of professions for the substance use disorder workforce, including psychiatrists, psychologists, physicians who are certified in addiction medicine, addiction counselors, social workers, nursing professionals, peer support professionals, and others. This legislation guides states in adopting a strategy that supports and advances immediate, intermediate, and long-term measures to build and sustain an SUD workforce....

November 19, 2024 | Innovative Initiatives, K-12 Education, Public Health, Substance Misuse

In the fall of 2022, West Virginia implemented an opioid and substance misuse prevention program named Game Changer in three public high schools. The first of its kind in the nation program uses student peer leadership programs that focus on building school environments that foster and promote healthy living and staying away from using or experimenting with alcohol and drugs....

November 15, 2024 | News Bites

Each issue of News Bites will highlight unique news articles from around the United States in the areas of public health and safety, substance use disorders, and the criminal justice system. This newsletter will feature stories that you may have missed but are important to the field....

November 5, 2024 | Controlled Substances, Medication Assisted Treatment (MAT), Opioids, Recovery, Reports & Studies, Treatments

The Heller School for Social Policy and Management at Brandeis University and the Legislative Analysis and Public Policy Association, together published a report that includes a comprehensive review of the laws and regulations that apply to methadone for opioid use disorder (OUD) to determine which laws and regulations would need to be amended in order to support pharmacy-based methadone treatment for OUD. This analysis (1) includes a discussion of the agencies involved in governing methadone for OUD treatment; (2) explains the provision in federal Controlled Substances Act that creates the regulatory scheme for methadone treatment; (3) describes DEA regulations governing Narcotic Treatment Programs; and (4) summarizes the general types of state laws and regulations that place additional restrictions on methadone for OUD treatment....

October 24, 2024 | Emergency Departments, Harm Reduction, Innovative Initiatives, Medication Assisted Treatment (MAT), Public Health, Recovery, Substance Misuse, Treatments

To complement the opioid prescribing guidelines that the University of Buffalo Department of Emergency Medicine established in 2016, Dr. Joshua Lynch developed the Medication for Addiction Treatment and Electronic Referrals (MATTERS) program. He saw the need for MATTERs because the “window of opportunity” to help someone with a substance use disorder is small, and he wanted to immediately link a patient who had overdosed to a treatment program that is right for that individual....

October 17, 2024 | First Responders, Harm Reduction, Model Laws, Naloxone, Opioid Antagonists, Opioid Antagonists, Recovery, Substance Misuse, Treatments

The key elements of the Model Overdose Reversal Agents Act are to: (1) remove all existing restrictions about who can receive, possess, store, transfer without cost, or administer an ORA such that any “person or entity” is eligible; (2) require specified individuals and entities to offer ORAs to individuals at increased risk of overdose; (3) require emergency access to ORAs at specified locations for use by any individual; (4) provide guidelines for ORA sales, in particular sales of non-prescription ORAs; (6) grant broad immunity to people or entities for prescribing, dispensing, giving, donating, transferring without charge, selling, or administering ORAs in the absence of gross negligence, malice, or criminal intent; (7) identify the required content for educational information about ORAs and specify when that information must be disseminated; (8) require Medicaid and other health insurance coverage for ORAs, including non-prescription ORAs, and prohibit discriminatory life and health insurance practices; and (9) create a bulk overdose reversal agent purchasing fund to assist persons and entities to fulfill requirements under the Act....

October 15, 2024 | Case Law Monitor

Case Law Monitor is the bimonthly case law newsletter of the Legislative Analysis and Public Policy Association (LAPPA). Each issue will highlight unique cases from around the United States in the areas of public health and safety, substance use disorders, and the criminal justice system. ...